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Over the past decade, non-coding RNAs (ncRNAs) have increasingly been recognized as key regulators of cel-
lular function in health and disease. ncRNAs have been 
studied both in the context of specific stroke etiologies, such 
as atherosclerosis, and in the context of stroke pathophysi-
ology, such as excitotoxicity. Moreover, their presence in the 
circulation has triggered the idea that ncRNAs might serve 
as biomarkers for specific disease states and thus guide clin-
ical decision-making. Accordingly, circulating ncRNAs have 
been the subject of multiple studies examining their potential 
clinical utility for risk prediction, diagnosis, and prediction 
of stroke outcome.
The abundancy of the ncRNA class is illustrated by the 
fact that, whereas about 3 quarters of the human genome are 
transcribed, <3 % are ultimately translated into proteins.1 
Also, the relative amount of DNA that is transcribed into 
ncRNA shows higher correlation with species complexity 
than the number of protein-coding genes,2 thus pointing to 
the functional relevance of ncRNAs. Beyond housekeeping 
ncRNAs, such as ribosomal and transfer RNA, this has mostly 
been attributed to the myriad of non-coding regulatory RNA 
classes. By convention, ncRNAs are divided into long non-
coding RNAs (lncRNAs) ≥200 nucleotides in length and 
small non-coding RNAs (<200 nucleotides), which include 
microRNAs (miRNAs), PIWI (P-element-induced wimpy 
testis-interacting) RNAs, and endogenous short interfering 
RNAs. Here, we summarize the emerging evidence for a reg-
ulatory role of miRNAs and lncRNAs in atherosclerosis and 
stroke pathophysiology. We further review current literature 
on their use as blood-based biomarkers and discuss opportu-
nities and challenges for future studies aiming at translation 
into clinical application in diagnostics and therapy.
ncRNAs: Biogenesis and Modes of Action
MicroRNAs
miRNAs encompass a class of >2000 small ncRNAs with 
a length of ≈22 nucleotides. Their biogenesis and function 
have been extensively reviewed3,4 and are summarized in 
Figure 1A. In short, depending on the developmental stage and 
cell type miRNA genes are transcribed into a primary hairpin 
miRNA. The Microprocessor complex, consisting of Drosha 
and DGCR8 (DiGeorge syndrome chromosomal region 8), 
cleaves the primary miRNA into a precursor miRNA. After 
nuclear export, the precursor miRNA is further processed by 
Dicer to generate a small RNA duplex. The functional guide 
strand of this duplex represents the mature miRNA and is 
loaded onto an Argonaute protein to form the RNA-induced 
silencing complex. Conformational rearrangements within 
the RNA-induced silencing complex allow the 6 to 8 nucleo-
tides long miRNA seed region to scan for target messenger 
RNAs (mRNA; Figure 1A).3 Binding of complementary target 
mRNAs evokes partial post-transcriptional silencing through 
mRNA destabilization and translational repression, thus lead-
ing to optimized or insufficient protein levels. Importantly, 
most miRNAs influence the expression of >1 target gene, 
which in turn may be regulated by >1 miRNA. Hence, phe-
notypic consequences may result from (I) 1 miRNA repress-
ing 1 target, (II) 1 miRNA repressing multiple targets, or (III) 
multiple miRNAs repressing the same or even different tar-
gets cumulating in the same phenotype.4 As such, miRNAs 
orchestrate cellular responses to pathophysiological stimuli. 
They are also present in blood and are protected from deg-
radation by inclusion in extracellular vesicles like exosomes, 
microvesicles, or apoptotic bodies, or by association with 
RNA-binding proteins or lipoprotein complexes (Figure 1A). 
miRNAs can further be actively secreted from cells, which in 
light of the role of exosomes and microvesicles in paracrine 
signaling, implies a potential function of miRNAs in intercel-
lular communication.5
Long noncoding RNAs
More than 58 000 transcripts represent the class of lncRNAs, 
some of them reaching several kilobases in length. They 
exhibit some coding function6 but, like miRNAs, mostly 
have regulatory function, thereby adding another layer to 
cellular regulatory networks. Depending on their genomic 
relation to protein-coding genes lncRNAs are classified as 
sense, antisense, intergenic, intronic, and bidirectional.7 
Their dynamic secondary and tertiary structures and ensu-
ing changes in binding sites allow them to interchangeably 
interact with DNA, other RNAs, and proteins. According 
to their molecular mechanism, lncRNAs can further be 
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organized within 4 not mutually exclusive classes: (1) signal 
lncRNAs, for example binding the chromatin remodeling 
and transcriptional machinery to silence transcription, (2) 
decoy lncRNAs, which bind and thereby expel proteins and 
miRNAs from their targets, (3) guide lncRNAs, for example 
chaperoning ribonucleoproteins to chromatin targets, and 
(4) scaffold lncRNAs, which bind distinct proteins to build 
complexes (Figure 1B). Depending on their cellular locali-
zation, lncRNAs may affect gene expression by binding the 
chromatin remodeling and transcriptional machinery in the 
nucleus or influence mRNA stabilization, translation, and 
decay in the cytoplasm (Figure 1B).7 Yet, owing to their 
more recent discovery, knowledge about the functional role 
of single lncRNAs is still limited when compared with miR-
NAs. Similar to miRNAs, lncRNAs have also been found to 
circulate in the blood where they are bound to protein com-
plexes or included in vesicles (Figure 1B).5
ncRNAs in Stroke Pathogenesis
The tissue- and developmental stage-dependent expression 
of ncRNAs indicates a high functional relevance in physio-
logical and disease processes. Several observations suggest a 
causal role of ncRNAs in stroke. First, genome-wide associ-
ation studies have identified a susceptibility locus for large-
vessel stroke on chromosome 9p21 harboring the lncRNA 
ANRIL (antisense ncRNA in the INK4 locus).8,9 Second, an 
analysis of 2763 participants from the population-based pro-
spective Framingham Heart Study found circulating miR-
656-3p and miR-941 to be associated with incident stroke.10 
Third, a highly penetrant mutation in a miR-29 binding site 
in the 3ʹ untranslated region of COL4A1 causes pontine 
autosomal dominant microangiopathy with leukoencepha-
lopathy (PADMAL).11 In accord with these findings, experi-
mental studies suggest a role of ncRNAs in key mechanisms 
of stroke pathogenesis, including atherosclerosis12 and atrial 
fibrillation.13 In the following, we will discuss ncRNAs with 
potential relevance to stroke prevention by influencing ather-
osclerosis (Table 1; Figure 2).
Atherosclerosis evolves across distinct stages including 
early dyslipidemia- and shear stress-mediated endothelial cell 
dysfunction, adhesion of leukocytes to endothelial cells, inva-
sion of leukocytes into the intima, migration, and prolifera-
tion of smooth muscle cells (SMC), development of a fibrous 
cap, and eventually plaque rupture (Figure 2).33 ncRNAs have 
been implicated in multiple aspects of atherogenesis. miR-33 
has been shown to promote early atherogenesis by regulat-
ing the biosynthesis of HDL (high-density lipoprotein) and 
the reverse cholesterol transport pathway. miR-33a and miR-
33b are located within introns of the genes encoding the 
sterol-regulatory element-binding factors and reduce circu-
lating HDL levels by targeting the ABC (ATP-binding cas-
sette) transporter ABCA1.20 Inhibition of miR-33 in both mice 
and monkeys increased plasma HDL levels20,21 and reduced 
plasma levels of VLDL (very-low-density lipoprotein)-associ-
ated triglycerides.21 Moreover, miR-33 antagonism promoted 
the accumulation of regulatory T cells and anti-inflamma-
tory macrophages within plaques, thereby leading to reduced 
plaque size in atherosclerosis-prone mice.34
Shear stress at predilection sites is another important fac-
tor aggravating endothelial dysfunction. Shear stress induces 
downregulation of miR-126-5p, the passenger strand of 
miR-126, in endothelial cells, and intravenous application 
of nanoparticle-carried miR-126-5p to atherosclerosis-prone 
mice for 4 weeks reduced aortic root lesion size by ≈75%,24 
thus highlighting the potential of miRNA-based interventions 
for atheroprotection.
After endothelial activation, inflammation of the arterial 
wall provokes the migration and proliferation of SMCs—a 
Figure 1. Biogenesis of microRNAs (miRNAs) and functions of long non-coding RNAs (lncRNAs). A, miRNA biogenesis is initiated in the nucleus (1–2) and com-
pleted in the cytoplasm (3–5). miRNAs escape degradation in blood by transportation in vesicles or by proteins (6). B, lncRNA functions can be categorized by 
molecular mechanism (1–4), cellular compartmentalization (1–3 vs 4–6) and by binding partners: DNA (3), RNA (5, 6), or proteins (1, 2, 4). Image by Dr Johannes 
Richers. AGO indicates Argonaute protein; pre-miRNA, precursor microRNA; pri-miRNA, primary microRNA; and RISC, RNA-induced silencing complex.
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process that is regulated by multiple ncRNAs. First, a circular 
ANRIL isoform inhibits proliferation and induces apoptosis of 
both SMCs and macrophages by negatively regulating ribo-
somal RNA maturation, thereby conferring atheroprotection.9 
Interestingly, linear ANRIL transcripts were found to exert 
atheroprogressive effects by trans-regulation of related gene 
networks.14 Second, the miR-143/miR-145 cluster promotes 
differentiation and represses proliferation of SMCs by re-
ducing KLF (Krüppel-like factor) 4 and KLF5 and increasing 
myocardin expression.27 miR-145 overexpression resulted in 
reduced plaque size and enhanced plaque stability.35 Notably, 
miR-143 and miR-145 have been shown to shuttle between 
endothelial cells and neighboring SMCs using extracellular 
vesicles and tunneling nanotubes,26 and thereby display syn-
ergistic atheroprotective effects in different cell types. Third, 
miR-21 enhances proliferation of SMCs, and its expression 
levels were elevated after in-stent restenosis.17 Both genetic 
ablation of miR-2117 and local delivery of anti-miR-21 by 
coated stents was protective by effectively reducing in-stent 
restenosis.36 However, ablating miR-21 in macrophages ac-
celerated atherosclerosis, including plaque necrosis by low-
ering cholesterol efflux and enhancing foam cell formation.18 
This may also explain why miR-21-deficient mice developed 
higher atherosclerotic burden, despite lacking SMC prolif-
eration. Local delivery of miR-21 using ultrasound-targeted 
microbubbles reversed the vulnerable carotid plaque phe-
notype.19 Hence, local delivery of miRNA-targeted drugs to 
overcome undesirable actions in other cell types might prove 
valuable for translating experimental findings to patients.
ncRNAs in Stroke Pathophysiology
Upon ischemia, brain cells undergo rapid changes in gene ex-
pression. Accordingly, both miRNAs37 and lncRNAs38 have 
been demonstrated to exert early expression changes in brain 
tissue after experimental ischemia. Both specific miRNAs and 
lncRNAs have been shown to regulate pathophysiological 
Table 1. Key ncRNAs Regulating Atherosclerosis
ncRNA Mechanism
ANRIL Linked to large-vessel stroke by multiple GWAS,8 ANRIL isoforms exert different functions: a circular ANRIL isoform inhibits proliferation of 
SMCs and macrophages,9 whereas linear ANRIL transcripts are atheroprogressive.14
lincRNA-p21 lincRNA-p21 confers atheroprotection by repressing proliferation and inducing apoptosis of SMCs and macrophages. Expression levels 
were reduced in atherosclerotic plaques in atherosclerosis-prone mice.15
MeXis The macrophage-expressed LXR-induced sequence (MeXis) guides the transcriptional coactivator DDX17 to amplify ABCA1 expression, 
thereby regulating cholesterol efflux and mediating atheroprotection.16
miR-21 miR-21 enhances proliferation of SMCs17 and cholesterol efflux from macrophages.18 Its ablation accelerated atherosclerosis including 
plaque necrosis despite decreasing SMC proliferation. Local delivery rescued the vulnerable plaque phenotype.19
miR-33a/b Intronically located within the SREBF genes, miR-33 has strongly been linked to the biosynthesis of HDL and the reverse cholesterol 
transport pathway. Its inhibition increased HDL levels and decreased VLDL levels.20,21
miR-92a The expression levels of this mechanosensitive miRNA are reduced in ECs on atheroprotective laminar flow patterns, thereby derepressing 
expression of the transcription factor KLF2 to maintain endothelial homeostasis.22
miR-122 This liver-enriched miRNA affects the expression of multiple genes in cholesterol biosynthesis.23 It was also the target of the pioneering 
use of chemically modified oligonucleotides in vivo.
miR-126-5p Shear stress reduces the expression of miR-126-5p in ECs, thereby diminishing the proliferative reserve of ECs. Long-term intravenous 
delivery of miR-126-5p reduced atherosclerotic plaque burden.24
miR-128 Proximally located to SNPs associated with abnormal blood lipids, miR-128 targets LDLR and ABCA1. Long-term inhibition decreased 
circulating total cholesterol levels by 35%.25
miR-143/-145 Shuttling between ECs and neighboring SMCs, miR-143 and miR-145 cooperate to maintain vessel wall function.26 By targeting KLF4 and 
KLF5 and enhancing myocardin expression, they repress proliferation of SMCs.27
miR-146a Expression of this cytokine-responsive miRNA in ECs is upregulated by proinflammatory cytokines. By targeting the NF-κB pathway, HuR, 
and the MAP kinase pathway, miR-146a blunts inflammation.28
miR-148a In addition to its proximity to SNPs associated with abnormal blood lipids (like miR-128), miR-148a was also identified in a screen for 
miRNAs to regulate LDLR expression. Long-term inhibition elevated plasma HDL-C and decreased LDL-C.25,29
miR-181b miR-181b represents another cytokine-responsive miRNA, whose expression in ECs is reduced in the course of atherosclerosis. By 
targeting the NF-κB pathway, miR-181b reduces leukocyte recruitment.30
miR-210 Unstable carotid plaques show decreased levels of miR-210. The delivery of miR-210 improved plaque stability by targeting APC, thereby 
affecting Wnt signaling and regulating SMC survival.31
miR-223 miR-223 regulates the expression of many genes involved in lipoprotein homeostasis, such as SCARB1, HMGCR, and SP3. Genetic ablation 
of miR-223 in mice resulted in increased HDL-C levels.32
ABCA1 indicates ATP-binding cassette transporter 1; APC, adenomatous polyposis coli; EC, endothelial cell; GWAS, genome-wide association study; HDL-C, high-
density lipoprotein cholesterol; HMGCR, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase; HuR, human antigen R; KLF2, Krüppel-like factor 2; LDL-C, low-density 
lipoprotein cholesterol; LDLR, LDL Receptor; LXR, liver X receptor; MAP, mitogen-activated protein; miRNA, microRNA; ncRNA, non-coding RNA; NF-κB, nuclear factor 
kappa-light-chain-enhancer of activated B cells; SCARB1, scavenger receptor class B type 1; SMC, smooth muscle cell; SNP, single-nucleotide polymorphism; VLDL, 
very-low-density lipoprotein; and Wnt, wingless-related integration site.
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processes after stroke, such as excitotoxicity, programmed 
cell death, inflammation, and blood-brain barrier breakdown 
(Figure 3), and, therefore, represent potential therapeutic tar-
gets in the acute and subacute phase of stroke.
In keeping with their capacity to fine-tune gene expression 
in regulatory networks, different ncRNAs have been shown to 
converge on the same pathophysiological mechanisms after 
stroke. For instance, >30 ncRNAs were reported to control 
programmed cell death after stroke (Figure 3). Conversely, 
many ncRNAs have been linked to more than a single process. 
A good example is miR-124, one of the most highly expressed 
miRNAs in the brain. miR-124 has been shown to regulate gene 
expression relevant for excitotoxicity, programmed cell death, 
inflammation, blood-brain barrier breakdown, angiogenesis, 
and neurogenesis after stroke (Figure 3). Accordingly, miR-
124 has been shown to regulate >100 genes when transfected 
into HeLa cells,39 which usually do not express miR-124. Yet, 
studies examining the effects of miR-124 poststroke have fo-
cused on single targets, such as the genes encoding iASPP40 
(an inhibitory member of the ASPP [apoptosis-stimulating 
proteins of p53] family) and Usp1441 (a deubiquitinating en-
zyme) and the effects of altered miR-124 levels on stroke out-
come are still debated.40,41 To fully understand the effects of 
miR-124 on gene expression poststroke and to elucidate the 
potential of miR-124-targeted therapeutics for application in 
human stroke, future studies will need to (1) determine the ki-
netics of miR-124 expression in different cell types and brain 
regions poststroke, (2) explore miR-124-mediated changes in 
gene expression poststroke, for example, by untargeted prote-
omic analysis, (3) characterize the cellular uptake of therapeu-
tics, their effects on miR-124 expression, and target repression 
in different cell types, and (4) determine their effects on the 
various mechanisms of stroke pathophysiology that have been 
linked to miR-124.
An example for the convergence of different ncRNAs on a 
specific pathophysiological mechanism is excitotoxicity, one of 
the earliest events after stroke (Figure 3). Aside from the effects 
of miR-124 on excitotoxicity, investigators found miR-223, a 
ubiquitously expressed miRNA, to decrease NMDA (N-Methyl-
D-aspartic acid)-mediated calcium influx. miR-223 limits exci-
totoxicity by targeting the glutamate receptor subunit genes 
GluR2 and NR2B and reduced lesion volume in a transient 
global ischemia model.42 Another study found miR-1000 in 
Drosophila and its mammalian homolog miR-137 in the mouse 
to be neuroprotective by repressing the expression of the ve-
sicular glutamate transporter.43 However, these findings await 
functional confirmation in experimental stroke models.
ncRNAs have further been implicated in programmed cell 
death poststroke. Yan et al44 even identified a functional link be-
tween a miRNA and the lncRNA MEG3. Specifically, MEG3 
was found to function as a sponge for miR-21 titrating it away 
from the programmed cell death 4 (PDCD4) mRNA. MEG3 
was elevated in brain tissue after transient focal ischemia, and 
its inhibition was associated with elevated levels of miR-21, 
decreased levels of PDCD4 and decreased infarct volume.44
miRNAs have further been linked to blood-brain barrier 
breakdown and microvascular integrity poststroke (Figure 3). 
Caballero-Garrido et al45 provided a rare example of an intrave-
nously administered miRNA-targeted therapeutic that reduced 
infarct volume when administered after experimental stroke. 
They identified inhibition of miR-155 as a promising approach 
to improve microvascular integrity, potentially mediated by el-
evated levels of RHEB (Ras homolog enriched in brain) and 
stabilization of ZO-1 (tight junction protein-1).45 The impact of 
miRNAs on microvascular integrity might also apply to hem-
orrhagic stroke: Xi et al46 demonstrated a beneficial effect of 
miR-126-3p on blood-brain barrier permeability, edema for-
mation, neuronal cell death, and functional outcome when 
administered after experimental intracerebral hemorrhage.
An unconventional way of signaling has been proposed for 
let-7 implicating a potential role in neurodegeneration after 
stroke: upon injury, cultured neurons released let-7, which in 
turn induced cell death via TLR (Toll-like receptor) 7 signal-
ing when added to neurons in vitro and in vivo.47 However, 
Figure 2. Non-coding RNAs (ncRNAs) regulating atherogenesis. Both specific long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been found 
to control distinct stages of atherosclerosis. Image by Dr Johannes Richers. SMC indicates smooth muscle cell.
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direct evidence for a relevant role of poststroke neuronal cell 
death mediated by endogenously released let-7 is still lacking.
Circulating ncRNAs as Biomarkers for the 
Diagnosis and Prognosis of Stroke
Owing to their cell type- and tissue-specific expression pat-
terns and remarkable stability in peripheral blood ncRNAs 
have become a prime target for stroke biomarker research. 
The majority of studies focused on circulating miRNAs as 
potential biomarkers of acute ischemic stroke (IS; Figure 4). 
However, circulating ncRNAs have also been studied to detect 
patients at risk for incident or recurrent stroke and to predict 
stroke outcome.
In the largest study to date, Mick et al10 profiled 2763 par-
ticipants of the Framingham Heart Study for circulating small 
ncRNAs to determine whether extracellular RNAs are associ-
ated with incident or prevalent stroke. Using quantitative real-
time polymerase chain reaction as a screening technique, they 
found miR-877-5p, miR-124-3p, miR-320d, and SNO1403 
to be associated with prevalent stroke, whereas miR-656-3p 
and miR-941 were associated with incident stroke.10 However, 
these findings still await confirmation in other populations.
Studies focusing on the acute phase of stroke have reported 
on a multitude of differentially regulated circulating ncRNAs 
(Figure 4). However, these findings were obtained using var-
iable platforms for ncRNA detection and variable strategies 
for blood sampling in terms of both type of specimens (eg, 
whole blood versus platelet-poor plasma) and timing after 
stroke onset, all of which may influence the results. Only 2 
studies explicitly restricted blood sampling to arrival in the 
emergency department (Figure 4),48,52 thus minimizing the po-
tential influence of early medication, such as heparin57 or anti-
platelet agents on the measurement of circulating miRNAs:
Tian et al48 examined plasma samples of 40 patients 
presenting within 6 hours of symptom onset and from 27 
healthy controls and applied a screening-and-validation 
approach that involved a microarray system in the screening 
phase. They identified 12 differentially expressed miRNAs, 
only one of which (miR-16-5p) could be validated in an in-
dependent sample with a sensitivity of 70% and a specificity 
of 87%.48 Extending these results, another study found the 
combination of miR-16-5p and miR-124-3p to differentiate 
ischemic from hemorrhagic stroke, although this study in-
cluded <100 patients, used a candidate rather than screening 
approach, lacked a validation sample, and did not provide 
data on sensitivity and specificity.58 Of note, other studies 
have used miR-16-5p as an endogenous standard to nor-
malize miRNA expression.54
We previously analyzed circulating miRNAs from plate-
let-poor plasma samples,52 thereby limiting a potential influ-
ence of residual platelets in blood specimens on the profile 
of circulating miRNAs.5 Other than previous studies on the 
acute phase after stroke, this study applied RNA sequencing 
for the screening stage. Through the use of 3 independent 
patient samples (overall N=492), we identified, validated 
(with quantitative real-time polymerase chain reaction), and 
Figure 3. Complex and overlapping regulation of stroke pathophysiology by non-coding RNAs (ncRNAs). Listing of ncRNAs that have been linked to specific 
mechanisms of stroke pathophysiology. References are listed in the Figure in the online-only Data Supplement. Owing to its regulation of 6 pathophysiological 
processes, miR-124 is emphasized by bold type. *Involved in more than a single process; **involved in at least 4 processes. BBB indicates blood-brain barrier.
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replicated a set of 3 miRNAs, miR-125a-5p, miR-125b-5p, 
and miR-143-3p (Figure 4). The sensitivity of this set to detect 
IS was superior to multimodal cranial computed tomography 
obtained for routine diagnostics.52 Hence, while circulating 
ncRNAs might aid in the diagnosis of patients with IS, careful 
selection of the sampling strategy (timing and type of sample) 
and detection platforms remains critical.
Given their involvement in stroke pathogenesis (Figure 2) 
and repair mechanisms (Figure 3) expression levels of specific 
circulating miRNAs might further aid in the prediction of stroke 
recurrence and stroke outcome. Aside from studies investigat-
ing miRNA-based prediction of outcome as one among other 
aspects, a study in 329 patients with IS specifically focused on 
outcome. In a candidate-approach using plasma sampled within 
72 hours of symptom onset miR-150-5p levels were found to 
improve risk classification for mortality at 90 days poststroke 
beyond traditional risk factors.59 In contrast, the relation of cir-
culating miRNAs and stroke recurrence has not been system-
atically addressed. However, the strong link between specific 
miRNAs and platelet function5 emphasizes their potential to 
assist in identifying patients at risk for stroke recurrence.
Other than serum and plasma, analysis of whole blood 
might enable the identification of ncRNAs regulating the func-
tional response of blood cells, such as the activation of leuko-
cytes. Dykstra-Aiello et al60 assessed the profile of lncRNAs in 
whole blood of 133 patients with IS and 133 healthy controls 
and found 396 differentially expressed lncRNAs, some of them 
mapping close to putative stroke risk genes. Hence, some of 
these lncRNAs might have relevance in mechanistically link-
ing stroke risk loci to blood cell responses after stroke.
Opportunities and Challenges
As outlined above potential clinical applications of ncRNAs 
include (1) the utilization of expression levels of circulating 
ncRNAs for prognostication and diagnosis, that is to predict 
stroke, to diagnose stroke in the acute phase, and to predict out-
come poststroke and (2) targeting their regulatory function for 
therapeutic purposes to prevent stroke and improve stroke out-
come. However, translating these findings into clinical appli-
cations requires more work including validation of diagnostic 
and preclinical therapeutic findings in multicenter studies.
A major difficulty in interpreting previous biomarker stud-
ies originates from inconsistencies between the sets of circu-
lating ncRNAs reportedly associated with stroke (Figure 4). 
Such inconsistencies are likely routed in the following fac-
tors, among others: (1) small sample sizes resulting in insuffi-
cient statistical power to capture true differences of hundreds 
of measured ncRNAs; (2) different recruitment strategies, 
inclusion and exclusion criteria resulting in differences in 
case mix, including age, sex, medication, and comorbidities, 
which are known to influence circulating ncRNA level vari-
ability5; (3) variable timing of blood sampling between and 
within studies, for example, when performed within the first 
72 hours, a highly dynamic period covering largely variable 
stroke-related pathophysiological processes (Figure 3). Also, 
patients receive medication after hospitalization, among them 
low-molecular-weight heparin, which has been shown to inter-
fere with the DNA polymerase during quantitative polymerase 
chain reaction57; (4) different blood specimens (serum versus 
plasma versus platelet-poor plasma). For instance, platelet ag-
gregation during serum preparation may result in release of 
platelet miRNAs, trapping of miRNA within aggregates, and 
degradation of miRNA carrier proteins by proteases activated 
during clotting5; (5) different protocols for RNA isolation61; 
and (6) different detection platforms, such as quantitative 
real-time polymerase chain reaction, microarrays, and RNA 
sequencing, differing in sensitivity, accuracy, throughput, and 
their ability to detect novel miRNAs.62
Figure 4. Challenges in interpreting studies investigating microRNAs (miRNAs) as biomarkers for acute ischemic stroke. Studies were selected that inves-
tigated the expression of at least 5 circulating miRNAs in patients within 72 h of symptom onset. miRNA nomenclature was unified to miRBase version 22. 
Highlighted miRNAs have been associated with ischemic stroke (IS) in more than a single study. Ag indicates Agilent; NA, no information available; PP-
plasma, platelet-poor plasma; and qRT-PCR, quantitative real-time polymerase chain reaction. *Sampling on hospital arrival by Tian et al48 and Tiedt et al52; † 
samples were pooled before the screening phase.
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To resolve the inconsistencies discussed above and facil-
itate the application of circulating ncRNA measurements to 
clinical diagnostic routine, a number of criteria should be met: 
(1) studies should be designed to target unmet clinical needs, 
which refers to any missing or inadequately performing com-
ponent of a clinical pathway63; (2) potential methodological 
confounders should be carefully considered (see above and 
reviewed in Sunderland et al5); (3) reports should adhere to the 
guidelines for the reporting of diagnostic studies64; and (4) ide-
ally, promising candidates should be validated in multicenter 
studies. Further, technological advances will overcome biases 
introduced by manual extraction methods and shorten pro-
cessing times. Emerging techniques to quantify miRNA levels 
directly without the need to extract RNA and synthesize cDNA 
include the single molecule array platform SIMOA, employing 
the detection of single miRNAs by magnetic beads coupled to 
miRNA detection probes65 and TORNADO (Theranostic One-
Step RNA Detector), a technology based on electrocatalytic 
platinum nanoparticles.66 Up to now, however, none of them 
has been applied in a clinical setting.
Other than diagnostic applications of ncRNAs, nu-
cleic acid-based therapies have already been approved by 
the US Food and Drug Administration, an example being 
Mipomersen, an antisense oligonucleotide targeting apoB 
to treat patients with homozygous familial hypercholester-
olemia.67 Expectations are that the development of ncRNA-
targeted therapeutics towards clinical applications in stroke 
will be facilitated by the following factors: (1) the advent 
of multilevel omics (eg, the application of parallel RNA 
sequencing and proteomics) will lead to the discovery of ad-
ditional ncRNAs representing central nodes in dysregulated 
networks of stroke pathophysiology; (2) the improvement 
of delivery vehicles for miRNA-targeted therapeutics will 
enable targeted cellular uptake, high stability, and efficient 
crossing of the blood-brain barrier. Careful monitoring of 
potential systemic toxicity is necessary, illustrated by the 
finding that specific chemical modifications of antisense oli-
gonucleotides to enhance uptake and stability in vivo have 
been shown to provoke platelet activation, aggregation, and 
thrombus formation68; and finally, (3) preclinical random-
ized controlled multicenter trials may be an informative step 
to select promising candidate ncRNAs before moving into 
patients (Table 2).69 Additional challenges in lncRNA re-
search include the presence of multiple transcript variants 
for individual lncRNAs, poor conservation, and the lack of a 
comprehensive and continuously updated database.
In conclusion, ncRNAs serve as central regulators of key 
pathological processes both before and after stroke. Circulating 
ncRNAs are dysregulated after stroke and might be used for 
diagnosis and prognosis to guide clinical decision-making. 
However, more work is needed to better delineate the involve-
ment of specific ncRNAs in stroke and to exploit their utility 
for clinical applications.
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